Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data [Yahoo! Finance]
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs [Yahoo! Finance]
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [Seeking Alpha]
Dyne Therapeutics (DYN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.